Department of Surgical and Clinical, Diagnostic and Pediatric Sciences, Section of Ophthalmology, University of Pavia-IRCCS Fondazione Policlinico San Matteo, Viale Camillo Golgi, 19, 27100, Pavia, Italy.
Centro Italiano Glaucoma, Milan, Italy.
Adv Ther. 2021 Aug;38(8):4403-4412. doi: 10.1007/s12325-021-01811-w. Epub 2021 Jul 12.
To evaluate the efficacy and safety of PreserFlo MicroShunt in primary open angle glaucoma (POAG) eyes after a single failed trabeculectomy.
Retrospective review of POAG eyes with a failed trabeculectomy that underwent PreserFlo MicroShunt implantation from March 2019 to November 2019, in two Italian glaucoma centers. Pre- and postoperative data were collected and compared.
A total of 31 surgeries in 31 patients were reviewed. Mean preoperative IOP and mean preoperative number of medications were 24.12 ± 3.14 mmHg and 3.29 ± 0.64, respectively, and decreased to 12.56 ± 2.64 mmHg and 0.46 ± 0.77 at the 12-month postoperative follow-up visit (p < 0.01). The most frequent adverse events were transient hypotony (6 eyes, 19.3%) and choroidal effusion (3 eyes, 9.6%). In all cases spontaneous resolution was observed, with no intervention.
In POAG eyes with a single failed trabeculectomy, the PreserFlo MicroShunt was safe and effective in reducing the IOP after a 12-month follow-up. The PreserFlo MicroShunt may represent a viable choice as a second surgery.
评估 PreserFlo MicroShunt 在单次失败的小梁切除术治疗原发性开角型青光眼(POAG)眼后的疗效和安全性。
回顾性分析 2019 年 3 月至 2019 年 11 月在意大利的两个青光眼中心接受 PreserFlo MicroShunt 植入术的失败性小梁切除术治疗的 POAG 眼。收集并比较术前和术后数据。
共回顾了 31 例 31 眼手术。平均术前眼压和平均术前用药数分别为 24.12±3.14mmHg 和 3.29±0.64,术后 12 个月随访时分别降至 12.56±2.64mmHg 和 0.46±0.77(p<0.01)。最常见的不良事件是短暂性低眼压(6 眼,19.3%)和脉络膜脱离(3 眼,9.6%)。所有病例均自发缓解,无需干预。
在单次失败的小梁切除术后的 POAG 眼中,PreserFlo MicroShunt 在 12 个月的随访中降低眼压是安全有效的。PreserFlo MicroShunt 可能是作为二次手术的可行选择。